頁籤選單縮合
題名 | 痛風合併慢性腎病之藥物治療=Drug Therapy in Gout with Chronic Kidney Disease |
---|---|
作者 | 楊璦瑜; 蔡憶萱; 郭震群; Yang, Ai-yu; Tsai, Yi-hsuan; Kuo, Chen-chun; |
期刊 | 藥學雜誌 |
出版日期 | 20171200 |
卷期 | 33:4=133 2017.12[民106.12] |
頁次 | 頁17-22 |
分類號 | 415.925 |
語文 | chi |
關鍵詞 | 痛風; 慢性腎臟疾病; 高尿酸血症; |
中文摘要 | 慢性腎臟疾病與高尿酸血症習習相關,而高尿酸血症是造成痛風最主要的風險因 子。高尿酸血症定義為血清尿酸濃度大於7.0 mg/dL。2016年歐洲風濕病聯盟 (EULAR) 建議,藥物治療的目標為一般痛風患者的血清尿酸值 < 6 mg/dL,痛風石的病人建議 < 5 mg/dL。痛風治療的目的包括治療急性發作、治療高尿酸血症、預防痛風再發作與降 低痛風併發症的風險。適當的選擇降尿酸藥物合併正確的劑量調整對痛風合併慢性腎 臟病人的用藥安全而言是重要的議題。 |
英文摘要 | Hyperuricemia is associated with risk of chronic renal disease, and hyperuricemia is recognized as a risk factor for gout. Hyperuricemia is defined as a serum uric acid concentration greater than 7.0 mg/dL. The 2016 European League Against Rheumatism (EULAR) recommended that the target of drug treatment was to achieve a serum uric acid level < 6 mg/dL in all gout patients or a serum uric acid level < 5 mg/dL for gout patients with tophi. Gout medications can be used to treat acute attacks, lowering serum urate levels and prevent future attacks as well as reduce your risk of complications from gout. It is important that appropriate select and dosage adjustment on treatment agents to improve drug safety in patients with gout and chronic kidney disease. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。